1 |
Cohort 1: hatg, csa, epag day 14 to month 6 |
Antilymphocyte immunoglobulin (horse) |
1件: D08808 D08808 💬 |
- |
- |
060 1件: 60 💬 |
2 |
Cohort 2: hatg, csa, epag day 14 to month 3 |
Antilymphocyte immunoglobulin (horse) |
1件: D08808 D08808 💬 |
- |
- |
060 1件: 60 💬 |
3 |
Cohort 3: hatg, csa (dose reduced), epag day 1 to month 6 |
Antilymphocyte immunoglobulin (horse) |
1件: D08808 D08808 💬 |
- |
- |
060 1件: 60 💬 |
4 |
Enalapril |
Enalapril |
2件: D00621 D00621, D07892 D07892 💬 |
ACE 1件: ACE 💬 |
Chagas disease 6件: Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system |
019 7件: 19, 46, 66, 113, 210, 222, 223 💬 |
5 |
Enalapril and other angiotensin converting enzyme inhibitors |
Angiotensin II |
4件: D00150 D00150, D00621 D00621, D02014 D02014, D07892 D07892 💬 |
ACE 3件: ACE, AGTR1, AGTR2 💬 |
AGE-RAGE signaling pathway in diabetic complications 18件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
019 1件: 19 💬 |
6 |
Enalapril maleate |
Enalapril |
2件: D00621 D00621, D07892 D07892 💬 |
ACE 1件: ACE 💬 |
Chagas disease 6件: Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system |
046 1件: 46 💬 |
7 |
Enalapril valsartan methylprednisone |
Enalapril |
3件: D00400 D00400, D00621 D00621, D07892 D07892 💬 |
ACE 2件: ACE, AGTR1 💬 |
AGE-RAGE signaling pathway in diabetic complications 18件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
066 1件: 66 💬 |
8 |
Epa |
- |
- |
- |
- |
008 6件: 8 , 46, 48, 49, 113, 301 💬 |
9 |
Epa and dha |
- |
- |
- |
- |
113 1件: 113 💬 |
10 |
Epa and dha supplementation |
- |
- |
- |
- |
048 2件: 48, 49 💬 |
11 |
Epadel |
- |
- |
- |
- |
296 1件: 296 💬 |
12 |
Epanova |
- |
- |
- |
- |
096 1件: 96 💬 |
13 |
Epanova™ (omega-3 free fatty acids) |
Omega-3 fatty acids |
- |
- |
- |
096 1件: 96 💬 |
14 |
Eparmefolin 30 cpr 0,1/0,5mg |
- |
- |
- |
- |
013 1件: 13 💬 |
15 |
Epatuzumab |
- |
- |
- |
- |
049 1件: 49 💬 |
16 |
Epax 6000 ee 1000mg (0.6 gr dha+epa) |
- |
- |
- |
- |
046 1件: 46 💬 |
17 |
Epaxal |
- |
- |
- |
- |
046 1件: 46 💬 |
18 |
Epaxal berna (virosomal hepatitis a vaccine) |
Hepatitis A Vaccine |
- |
- |
- |
096 2件: 96, 97 💬 |
19 |
Ethyl-epa |
Icosapent ethyl |
1件: D01892 D01892 💬 |
- |
- |
008 1件: 8 💬 |
20 |
Ethyl-epa (miraxion™) |
Icosapent ethyl |
1件: D01892 D01892 💬 |
- |
- |
008 1件: 8 💬 |
21 |
Hepatitis a vaccine ( havrix or epaxal) |
Hepatitis A Vaccine |
- |
- |
- |
046 1件: 46 💬 |
22 |
Over the counter dha/epa dietary supplementation |
- |
- |
- |
- |
301 1件: 301 💬 |